Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings
Multiple sclerosis (MS) is a chronic autoimmune neurological disease that typically affects young adults, causing irreversible physical disability and cognitive impairment. Alemtuzumab, administered intravenously as 2 initial courses of 12 mg/day (5 consecutive days at baseline, and 3 consecutive da...
Main Authors: | Krista Barclay, Robert Carruthers, Anthony Traboulsee, Ann D. Bass, Christopher LaGanke, Antonio Bertolotto, Aaron Boster, Elisabeth G. Celius, Jérôme de Seze, Dionisio Dela Cruz, Mario Habek, Jong-Mi Lee, Volker Limmroth, Sven G. Meuth, Celia Oreja-Guevara, Patricia Pagnotta, Cindy Vos, Tjalf Ziemssen, Darren P. Baker, Bart Van Wijmeersch |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-03-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2019.00253/full |
Similar Items
-
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
by: Antonio Bertolotto, et al.
Published: (2020-05-01) -
Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
by: Katja Akgün, et al.
Published: (2020-01-01) -
Inclusion Body Myositis Treated with Alemtuzumab
by: Juliana Sá, et al.
Published: (2019-12-01) -
Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
by: Tjalf Ziemssen, et al.
Published: (2021-08-01) -
Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
by: Jürgen Haas, et al.
Published: (2019-06-01)